Animal-induced injuries and disease, neonatal jaundice, immunizations, and viral infections

Current Opinion in Pediatrics

Volumn 8, Issue 4, 1996, Pages 417-425

  Gerson, William T ^a  

^a Pediatric Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DOXYCYCLINE; HEPATITIS A VACCINE; IMMUNOGLOBULIN; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE;

BITE; CAT SCRATCH DISEASE; CHICKENPOX; CHILD; CLINICAL TRIAL; DOG BITE; DRUG COST; EHRLICHIOSIS; HEPATITIS A; HUMAN; IMMUNIZATION; NEWBORN JAUNDICE; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; PRIORITY JOURNAL; PRIVATE PRACTICE; RABIES; REVIEW; SALMONELLOSIS; STREPTOCOCCUS INFECTION; VIRUS INFECTION;

EID: 0029831559     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199608000-00021     Document Type: Review

References (69)

1. Sacks JJ, Lockwood R, Hornreich J, Sattin RW: Fatal dog attacks, 1989-1994. Pediatrics 1996, 97:891-895.
2. Kneafsey B, Condon FC: Severe dog-bite injuries, introducing the concept of pack attack: a literature review and seven case reports. Injury 1995, 26:37-41.
3. Sinclair CL, Zhou C: Descriptive epidemiology of animal bites in Indiana, 1990-92: a rationale for intervention. Public Health Rep 1995, 110:64-67. Addresses the epidemiologic basis and justification for a bite prevention program targeted toward children. Analyzes animal bite data from Indiana for the years 1990 to 1992 looking for trends that might be useful for preventive intervention. Highest incidence was noted for children 5 to 9 years of age. The dog and cat were the most commonly reported biting animals. Wild and pet rodents were the next most frequent biting group. The incidence of bites peaked in the spring. Urban counties reported higher bite rates than nonurban counties; however, reporting bias probably tends to favor underreporting in rural areas. The authors suggest incorporating animal bite education into the kindergarten through grade four curriculum to match the peak age incidence. Timing educational intervention in the springtime was also suggested to match the peak seasonal incidence. Keeping of pet wildlife is to be discouraged.
4. Mathews JR, Lattal KA: A behavioral analysis of dog bites in children. J Dev Behav Pediatr 1994, 15:44-52.
5. Wilson KS, Maroney SA, Gander RM: The family pet as an unlikely source of group A beta-hemolytic streptococcal Infection in humans. Pediatr Infect Dis J 1995, 14:372-375. The family pet is not to be blamed for recurrent GABS.
6. Demers DM, Bass JW, Vincent JM, Person DA, Noyes DK, Staege CM, Samlaska CP, Lockwood NH, Regnery RL, Anderson, BE: Cat-scratch disease in Hawaii: etiology and seroepidemiology. J Pediatr 1995, 127:23-26. Cat scratch disease in Hawaii is due to B. henselae and is directly linked to the bite or scratch of a kitten. Older cats seldom have bacteremia but often have serologic evidence of past infection. Dogs were not implicated in the epidemiology of CSD. A. felis was not etiologically implicated in CSD in the animals or humans studied. Symptom-free, flea-infested kittens with B. henselae bacteremia are the major reservoir of the organism, and the organism may spread from kitten to kitten by way of their fleas. The indirect fluorescence antibody test is now the method of choice for laboratory diagnosis of CSD.
7. Szelc-Kelly CM, Goral S, Perez-Perez GI, Perkins BA, Regnery, RL, Edwards KM: Serologic responses to Bartonella and Afipia antigens in patients with cat scratch disease. Pediatrics 1995, 96:1137-1142. More evidence that the causitive agent of CSD is from the Bartonella genus. A. felis was not implicated as a causative agent. Serologic testing for CSD should be commercially available once standardization and further testing are completed.
8. Jameson P, Greene C, Regnery R, Dryden M, Marks A, Brown J, Cooper J, Glaus B, Greene R: Prevalence of Bartonella henselae antibodies in pet cats throughout regions of North America. J Infect Dis 1995, 172:1145-1149.
9. Centers for Disease Control: Reptile-associated salmonellosis: selected states, 1994-1995. MMWR Morbid Mortal Wkly Rep 1995, 44:347-350.
10. Ackman DM, Drabkin P, Birkhead G, Cieslak P: Reptile-associated salmonellosis in New York State. Pediatr Infect Dis J 1995, 14:955-959.
11. Centers for Disease Control: African pygmy hedgehog-associated salmonellosis: Washington, 1994. MMWR Morbid Mortal Wkly Rep 1995, 44:462-463.
12. Centers for Disease Control: Outbreak of salmonellosis associated with beef jerky: New Mexico, 1995. MMWR Morbid Mortal Wkly Rep 1995, 44:785-788.
13. Centers for Disease Control: Outbreak of trichinellosis associated with eating cougar jerky: Idaho. 1995. MMWR Morbid Mortal Wkly Rep 1996, 44:205-206.
14. Centers for Disease Control: Human rabies: Alabama, Tennessee, and Texas, 1994. MMWR Morbid Mortal Wkly Rep 1995, 44:269-272
15. Centers for Disease Control: Human rabies: Connecticut, 1995. MMWR Morbid Mortal Wkly Rep 1996, 45:207-209.
16. Centers for Disease Control: Human rabies: California, 1995. MMWR Morbid Mortal Wkly Rep 1996, 45:353-356.
17. Centers for Disease Control: Human rabies: Washington, 1995. MMWR Morbid Mortal Wkly Rep 1995, 44:625-627.
18. Centers for Disease Control: Mass treatment of humans exposed to rabies: New Hampshire, 1994. MMWR Morbid Mortal Wkly Rep 1995, 44:484-486.
19. Centers for Disease Control: Human granulocytic ehrlichiosis: New York, 1995. MMWR Morbid Mortal Wkly Rep 1995, 44:593-595.
20. Standaert SM, Dawson JE, Schaffner W, Childs JE, Biggie KL, Singleton J Jr, Gerhardt RR, Knight ML, Hutcheson RH: Ehrlichiosis in a golf-oriented retirement community. N Engl J Med 1995, 333:420-425. Another reason not to play golf. Or, it is better to be a good golfer than one who is always searching in the woods for that lost ball. In investigating a large outbreak of ehrlichiosis in Tennessee by means of a case-control epidemiologic study, the authors identified tick bites, exposure to wildlife, golfing, and among golfers, retrieving lost golf balls from the rough as risk factors in acquiring E. chaffeensis infection. Insect repellent was protective.
21. Fishbein DB: Tick-borne diseases: a growing risk. N Engl J Med 1995, 333:452-453. Of note, chloramphenicol is not the drug of choice for ehrlichiosis, or for Rocky Mountain spotted fever. Tetracycline therapy should yield a clinical response in 24 to 48 hours in both forms of ehrlichiosis and Rocky Mountain spotted fever, thus also being helpful in support of this presumptive diagnosis.
22. Goodman JL, Nelson C, Vitale B, Madigan JE, Dumler JS, Kurtti TJ, Munderloh, UG: Direct cultivation of the causitive agent of human granulocytic ehrlichiosis. N Engl J Med 1996, 334:209-215. The ability to grow the infectious agent causing HGE should help further understand the epidemiology, pathophysiology, and treatment of the disease.
23. Schaffner W, Standaert SM: Ehrlichiosis: In pursuit of an emerging infection. N Engl J Med 1996, 334:262-263.
24. Telford SR III, Lepore TJ, Snow P, Warner CK, Dawson JE: Human granulocytic ehrlichiosis in Massachusetts. Ann Intern Med 1995, 123:277-279.
25. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler S: Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996, 275:199-205. Currently the quickest and most practical method for diagnosis of HGE is the microscopic examination of the acute-phase blood smear to detect neutrophilic morulae. All patients were febrile and virtually all experienced malaise, rigors, myalgias, sweats, and headache.
26. Walker DH. Human ehrlichiosis: more trouble from ticks. Hosp Pract 1996, 31:47-57.
27. Walker DH, Barbour AG, Oliver JH, Lane RS, Dumler S, Dennis DT, Persing DH, Azad AF, McSweegan E: Emerging bacterial zoonotic and vector-borne diseases. JAMA 1996, 275:463-469.
28. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia: Practice parameter: management of hyperbilirubinemia in the healthy term newborn. Pediatrics 1994, 94:556-565.
29. Braveman P, Egeter S, Pearl M, Marchi K, Miller C: Early discharge of newborns and mothers: a critical review of the literature. Pediatrics 1995, 96:716-726. In the absence of data, we should move cautiously and avoid generalizations in matters of newborn and maternal discharge. Published studies provide little knowledge of the consequences of early discharge in the general population. Studies that have concluded that early discharge was safe were applied under restricted circumstances or were too small to detect clinically significant effects on important outcomes. Rigorous studies of sufficient size to provide statistical power are needed. Unfortunately, market forces weigh heavily on practice management. Without outcome data we have nothing smart to say.
30. Avorn J: Practice-based outcomes research: crucial, feasible, and neglected. Pediatrics 1996, 97:113-114.
31. Kessel W, Kiely M, Nora AH, Sumaya CV: Early discharge: in the end, it is judgment Pediatrics 1995, 96:739-745.
32. Seidman DS, Stevenson DK, Ergaz Z, Gale R: Hospital readmission due to hyperbilirubinemia. Pediatrics 1995, 96:727-729. Based on the study population of 6705 healthy, full-term infants in Israel, 0.36% of such infants may develop severe hyperbilirubinemia in the first postnatal week.
33. Maisels MJ, Newman TB: Kernicterus in otherwise healthy, breast-fed term infants. Pediatrics 1995, 96:730-733.
34. Koff RS: Seroepidemiology of hepatitis A in the United States. J Infect Dis 1995, 171(suppl 1):S19-23. Hepatitis A virus is shed in the stool. As a consequence, the predominant mode of spread is fecal-oral. Common source vectors include contaminated foods, water, and bivalve mollusks. Risk factors include contact with a person with hepatitis A, day care exposure, international travel, exposure to contaminated food or water during an outbreak, homosexual activity, and intravenous drug use. No known risk factors are identified in many cases.
35. Margolis HS, Alter MJ: Will hepatitis A become a vaccine-preventable disease? Ann Intern Med 1995, 122:464-465.
36. Balcarek KB, Bagley R, Pass RF, Schiff ER, Krause DS: Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995, 171(suppl 1):S70-72.
37. Melnick JL: History and epidemiology of hepatitis A virus. J Infect Dis 1995, 171(suppl 1):S2-8.
38. Centers for Disease Control: Licensure of inactivated hepatitis A vaccine and recommendations for international travelers' use. MMWR Morbid Mortal Wkly Rep 1995, 44:559-560.
39. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapoong T, Safary A, Tang DB, Boslego JW: Protection against hepatitis A by an inactivated vaccine. JAMA 1994, 271:1328-1334.
40. Hollinger FB, Eickhoff T, Gershon A, Jong EC, Koff RS: Discussion: who should receive hepatitis A vaccine? A strategy for controlling hepatitis A in the United States. J Infect Dis 1995, 171(suppl 1):S73-77.
41. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S: Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974, 2:1288-1290.
42. Plotkin SA: Varicella vaccine. Pediatrics 1996, 97:251-253.
43. Gershon A: Varicella vaccine: its past, present and future. Pediatr Infect Dis J 1995, 14:742-744.
44. Krause PR, Klinman DM: Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 1995, 127:518-525. Studies involving approximately 11,000 children and adults followed up for periods ranging from 2 to 12 years provide the evidence for the safety and efficacy of Varivax (Merck & Co., West Point, PA) that led to its licensure by the US Food and Druge Administration. More than 3 million doses of the Oka strain-based varicella vaccine have been safely administered worldwide. Universal varicella immunization will improve the health of America's children. Merck and the CDC have committed themselves to postmarketing surveillance.
45. Centers for Disease Control: Recommended childhood vaccination schedule: United States, January-June, 1996. MMWR Morbid Mortal Wkly Rep 1996, 44:942-943. Universal varicella vaccination is recommended between 12 and 18 months of age. Unvaccinated children who lack a reliable history of chickenpox should be vaccinated at the age of 11 to 12 years. Adolescents who have not received three doses of hepatitis B vaccine should initiate or complete the series at the age of 11 to 12 years.
46. Asano Y, Nagai T, Miyata T, Yazaki T, Shigemitsu I, Yamanishi K, Takahashi M: Long-term protective immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 1985, 75:667-671.
47. Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yasaki T, Shibata M, Tsuzuki K, Ito S: Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994, 94:524-526.
48. Watson B, Gupta R, Randall T, Starr S: Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J Infect Dis 1994, 169:1387-1388.
49. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM: Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 Infants and adolescents. Pediatr Infect Dis J 1995, 14:874-879.
50. Watson B, Rothstein E, Bernstein H, Arbeter A, Arvin A, Chartrand S, Clements D, Kumar M, Reisinger K, Blatter M, et al.: Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 1995, 172:217-219.
51. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, Cnaan A, Starr SE: Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995, 20:316-319.
52. Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H, Keller P, Arvin A, Watson B, White CJ, Varivax Study Group: Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 1996, 15:49-54.
53. Nader S, Bergen R, Sharp M, Arvin AM: Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 1995, 171:13-17.
54. Choo PW, Donahue JG, Manson JAE, Platt R: The epidemiology of varicella and its complications. J Infect Dis 1995, 172:706-712.
55. IIV) in healthy children. J Infect Dis 1996, 173:731-734.
56. Oshiro AC, Begue RE, Steele RW: Varicella disease and transmission in pediatric house officers. Pediatr Infect Dis J 1996, 15:461-462.
57. Grossman M: Varicella vaccine and health care workers. Pediatr Infect Dis J 1996, 15:395-396.
58. Ecevit Z, Buyukpamukcu M, Kanra G, Sevinir B, Ueda S: Oka strain live varicella vaccine in children with cancer. Pediatr Infect Dis J 1996, 15:169-170.
59. Marwick C: ACIP moves ahead with plans for use of IPV. JAMA 1995, 274:1417-1418.
60. Centers for Disease Control: Progress toward global poliomyelitis eradication, 1985-1994. MMWR Morbid Mortal Wkly Rep 1995, 44:273-281.
61. Hull HF, Lee JW: Sabin, Salk, or sequential? Lancet 1996, 347:630.
62. Plotkin SA: Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J 1995, 14:835-839.
63. Marwick M: Not everyone wants IPV; opposition gears up. JAMA 1995, 274:1574-1575.
64. Smith JC, Haddix AC, Teutsch SM, Glass RI: Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995, 96:609-615. Rotavirus is the single most common cause of severe diarrhea in children worldwide. Economic and disease reduction benefits would be realized from the use of a rotavirus vaccine. Given the reasonable parameters used in this decision analysis model, current vaccines are clearly cost effective.
65. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichero ME, Zito ET, Mack ME, Davidson BL, Kapakian AZ, for the United States Rotavirus Vaccine Efficacy Group: Safety and efficacy of high-dose rhesus-human reassortment rotavirus vaccines: report of the national multicenter trial. Pediatrics 1996, 97:7-13. A large, randomized, multicenter, placebo-controlled trial covering one rotaviral season in 1278 healthy infants. Vaccination was most protective against serious illness. Tetravalent RRV prevented 49% of rotavirus episodes, 80% of severe episodes, and 100% of dehydrating rotavirus illness. Efficacy figures from vaccine trials cannot be directly extrapolated to vaccine effectiveness after routine use (eg, for use in decision analysis models), because not all susceptible children will be immunized before exposure. Also, because this study covered only one season, decreased protective efficacy would be expected during subsequent seasons.
66. Glass RI, Gentsch JR, Ivanoff B: New lessons for rotavirus vaccines. Science 1996, 272:46-48.
67. Rennels MB, Wasserman SS, Glass RI, Keane VA, for the US Rotavirus Vaccine Efficacy Group: Comparison of immunogenicity and efficacy of rhesus rotavirus reassortment vaccines in breastfed and nonbreast-fed children. Pediatrics 1995, 96:1132-1136.
68. Rennels MB, Ward RC, Mack ME, Zito ET, for the US Rotavirus Efficacy Group: Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects of immune responses to both vaccines and on efficacy of rotavirus vaccines. J Infect Dis 1996, 173:306-313.
69. Pickering LK, Morrow AL, Herrera I, O'Ryan M, Estes MK, Guilliams SE, Jackson L, Carter-Campbell S, Matson DO: Effect of maternal rotavirus immunization on milk and serum antibody titers. J Infect Dis 1995, 172:723-728.